Cargando…
Pilot study: management with pentoxifylline in patients with chronic liver disease and COVID-19
INTRODUCTION AND OBJECTIVES: This study aimed to improve the response to adjuvant treatment with pentoxifylline in patients with SARS-CoV-2 and previous chronic liver disease. MATERIALS AND METHODS: In the ISSSTE hospital of Zapopan for eight months, 51 patients with moderate to severe SARS-CoV-2 an...
Autores principales: | Jiménez-Luévano, MA, Jiménez-Partida, AE, Jiménez-Partida, MA, Bravo-Cuellar, A, Cortes-Aguilar, Y |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier España, S.L.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713531/ http://dx.doi.org/10.1016/j.aohep.2022.100838 |
Ejemplares similares
-
Manifestations of SARS-COV-2 in patients with chronic liver disease
por: Jiménez-Partida, AE, et al.
Publicado: (2022) -
Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study
por: Maldonado, Valente, et al.
Publicado: (2021) -
A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19
por: Mostafa-Hedeab, Gomaa, et al.
Publicado: (2022) -
Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline
por: Cioboată, Ramona, et al.
Publicado: (2017) -
COVID–19-associated diffuse dermal angiomatosis managed with pentoxifylline and topical timolol
por: Toker, Michelle, et al.
Publicado: (2023)